Targeting calcium signaling in cancer therapy.
10.1016/j.apsb.2016.11.001
- Author:
Chaochu CUI
1
;
Robert MERRITT
2
;
Liwu FU
3
;
Zui PAN
2
;
Author Information
1. State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Department of Surgery, Division of Thoracic Surgery, The Ohio State University, Columbus, OH 43210, USA.
2. Department of Surgery, Division of Thoracic Surgery, The Ohio State University, Columbus, OH 43210, USA
3. State Key Laboratory of Oncology in South China
- Publication Type:Journal Article
- Keywords:
20-GPPD, 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol;
Apoptosis;
CBD, cannabidiol;
CBG, cannabigerol;
CPZ, capsazepine;
CRAC, Ca2+ release-activated Ca2+ channel;
CTL, cytotoxic T cells;
CYP3A4, cytochrome P450 3A4;
Ca2+ channels;
CaM, calmodulin;
CaMKII, calmodulin-dependent protein kinase II;
Cancer therapy;
Cell proliferation;
Channel blockers;
ER/SR, endoplasmic/sarcoplasmic reticulum;
HCX, H+/Ca2+ exchangers;
IP3, inositol 1,4,5-trisphosphate;
IP3R (1, 2, 3), IP3 receptor (type 1, type 2, type 3);
MCU, mitochondrial Ca2+ uniporter;
MCUR1, MCU uniporter regulator 1;
MICU (1, 2, 3), mitochondrial calcium uptake (type 1, type 2, type 3);
MLCK, myosin light-chain kinase;
Migration;
NCX, Na+/Ca2+ exchanger;
NF-κB, nuclear factor-κB;
NFAT, nuclear factor of activated T cells;
NSCLC, non-small cell lung cancer;
OSCC, oral squamous cell carcinoma cells;
PKC, protein kinase C;
PM, plasma membrane;
PMCA, plasma membrane Ca2+-ATPase;
PTP, permeability transition pore;
ROS, reactive oxygen species;
RyR, ryanodine receptor;
SERCA, SR/ER Ca2+-ATPase;
SOCE, store-operated Ca2+ entry;
SPCA, secretory pathway Ca2+-ATPase;
Store-operated Ca2+ entry;
TEA, tetraethylammonium;
TG, thapsigargin;
TPC2, two-pore channel 2;
TRIM, 1-(2-(trifluoromethyl) phenyl) imidazole;
TRP (A, C, M, ML, N, P, V), transient receptor potential (ankyrin, canonical, melastatin, mucolipin, no mechanoreceptor potential C, polycystic, vanilloid);
VGCC, voltage-gated Ca2+ channel;
mAb, monoclonal antibody
- From:
Acta Pharmaceutica Sinica B
2017;7(1):3-17
- CountryChina
- Language:English
-
Abstract:
The intracellular calcium ions (Ca) act as second messenger to regulate gene transcription, cell proliferation, migration and death. Accumulating evidences have demonstrated that intracellular Cahomeostasis is altered in cancer cells and the alteration is involved in tumor initiation, angiogenesis, progression and metastasis. Targeting derailed Casignaling for cancer therapy has become an emerging research area. This review summarizes some important Cachannels, transporters and Ca-ATPases, which have been reported to be altered in human cancer patients. It discusses the current research effort toward evaluation of the blockers, inhibitors or regulators for Cachannels/transporters or Ca-ATPase pumps as anti-cancer drugs. This review is also aimed to stimulate interest in, and support for research into the understanding of cellular mechanisms underlying the regulation of Casignaling in different cancer cells, and to search for novel therapies to cure these malignancies by targeting Cachannels or transporters.
